Nishimoto Clinic

VACCINATION & PREVENTION

COVID-19 and influenza vaccines at the same visit

We recommend receiving influenza and COVID-19 vaccines at the same visit for adults aged 65 or older and other patients at higher risk of severe illness.

The main aim is to reduce severe illness and burdens such as hospitalization. We discuss vaccination in light of your health, vaccination history, previous reactions and preferences.

Medically reviewed by Koshiro Nishimoto, MD, PhD (Director)

Updated October 9, 2026

A US study of nearly 300,000 people

A study published in The New England Journal of Medicine (NEJM) in 2025 used US Veterans Affairs health records to examine the association between 2024–2025 COVID-19 vaccination and subsequent COVID-19-associated emergency visits, hospitalizations and deaths.

People included in the comparison295,971 people

Influenza + COVID-19

Both vaccines on the same day164,132 people

Influenza only

No COVID-19 vaccine on that day131,839 people

Clinic-created diagram based on the included participant counts in the original Fig. 1.

Follow-up lasted up to 180 days from vaccination. Using an influenza-vaccinated comparison group helps reduce differences related to vaccination habits and use of health care.

All participants had received at least one 2023–2024 COVID-19 vaccine dose. The study therefore assessed the additional benefit of the updated seasonal dose, rather than comparing vaccination with never having been vaccinated.

NEJM original article: methods and Fig. 1

How did the estimated risks differ?

After statistical adjustment for differences such as age and medical conditions, the group receiving both vaccines had lower estimated risks of COVID-19-associated emergency visits, hospitalizations and deaths.

Estimated risks over 180 days

All bars use the same scale, from 0 to 0.8%.

Emergency or urgent care visit

Relative reduction: 29.3%
Influenza only0.624%
Both vaccines0.442%

Hospitalization

Relative reduction: 39.2%
Influenza only0.191%
Both vaccines0.116%

Death within 30 days of a positive test*

Relative reduction: 64.0%
Influenza only0.0349%
Both vaccines0.0125%

Any of the three outcomes

Relative reduction: 28.3%
Influenza only0.642%
Both vaccines0.460%

Clinic-created chart using the adjusted 180-day estimates in NEJM Table 2. Both vaccines means influenza and COVID-19 vaccines on the same day.

*Death was defined as death within 30 days after a positive SARS-CoV-2 test, without restriction by cause. Other causes may be included if that condition is met; deaths without a qualifying positive test are not counted in this endpoint. The study did not evaluate adverse events or vaccine-attributable deaths and cannot determine safety or the overall effect on all-cause mortality.

NEJM original article: Table 2 and Fig. 2

Safety of same-day vaccination

Influenza and COVID-19 vaccines may be given at the same visit when the doctor considers it medically appropriate. This can reduce the number of visits needed for vaccination.

Reactions may include pain at the injection site, fatigue, headache or fever. Some studies report more temporary reactions with coadministration, so we review your health and previous reactions before vaccination.

Rare serious allergic reactions (anaphylaxis) and myocarditis or pericarditis have also been reported. The following US mRNA COVID-19 vaccine data provide reference estimates of frequency.

Rare adverse-event frequency: US reference data per dose
Adverse eventEstimated percentagePopulation and observation period
AnaphylaxisAbout 0.0005%mRNA vaccines. Estimate in current CDC guidance, based on the original-formula primary series in people aged 12 or older, on vaccination day and the following day.
Myocarditis or pericarditisAbout 0.0008%2023–2024 mRNA formulation, ages 6 months through 64 years; 1–7 days after vaccination.
Myocarditis or pericarditis (young males)About 0.0027%The same 2023–2024 data, males aged 12–24; 1–7 days after vaccination.

CDC: anaphylaxis frequency / FDA: myocarditis/pericarditis frequency, June 2025

Seek prompt medical attention for chest pain, difficulty breathing or palpitations after vaccination.

Japan Ministry of Health: coadministration and adverse reactions (Japanese) / Japanese Association for Infectious Diseases recommendations (Japanese)

Fees, questions and appointments

All listed amounts include tax.

For eligible routine-program recipients aged 65 or older who are registered residents of Miyazaki City, patient contributions for fiscal year 2026 are:

Influenza vaccine
¥1,500
COVID-19 vaccine
¥4,500
Both vaccines at the same visit
Total ¥6,000

The routine COVID-19 vaccination period is October 1, 2026 through March 31, 2027. Recipients of public assistance are exempt from both contributions on presentation of their certificate.

The routine program also includes residents aged 60–64 with specified severe heart, kidney or respiratory impairment that profoundly limits daily activities, or HIV-related immune impairment that makes daily life almost impossible. A medical recommendation does not by itself establish eligibility for the public program.

For other patients, we explain eligibility and costs individually. If your registered residence is outside Miyazaki City, check your municipality’s current program.

Miyazaki City fiscal year 2026 vaccination program (Japanese) / Clinic fees

Tell reception or your doctor that you would like influenza and COVID-19 vaccines at the same visit. We review your medical conditions, treatment, vaccination history and previous reactions, then explain scheduling and appointment arrangements.

Please also tell us if you recently had COVID-19 and when it occurred. We discuss whether and when to vaccinate in light of your health and treatment.

This page provides general patient information. Individual suitability for vaccination is assessed during consultation.

CallBook online